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Genetic variation in the SLC2A9 gene is a new genetic risk
factor for low fractional excretion of uric acid, hyperuricemia,
and gout. Its gene product, GLUT9, was previously known as
a type II glucose/fructose transporter but is now known
to function as a high-capacity uric acid transporter that
is expressed in kidney, liver, and several other tissues.
Follow-up meta-analyses, including one with data from
28,141 individuals, implicated a total of nine additional
loci influencing serum urate concentrations, including six
other membrane transporters (SLC17A1, SLC17A3, SLC22A11,
SLC22A12, SLC16A9, and ABCG2). Variants in these genes
together account for about 5% of the variance in serum
urate, two-thirds of which is due to SLC2A9. Using these
variants in ‘Mendelian randomization’ analyses provides
a powerful means of dissecting the role of urate in
cardiovascular and metabolic diseases, where cause-and-
effect influences are difficult to discern due to potential
confounding. The results highlight the complex interplay
of membrane transporters involved in urate metabolism.
They also show how variants of weak effect identified by
genome-wide association studies can still be important in
identifying novel pathways, including a ‘complexity’ of
new and potentially druggable targets for modifying urate
transport.
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Uric acid is the end product of purine metabolism in
humans, higher primates, and only a small number of other
species.1 In other (ureotelic) mammals, urate is metabolized
by urate oxidase (uricase) to the more soluble product
allantoin, which is readily excreted in the urine. This is
not the case in lineages leading to the lesser apes and great
apes/humans, respectively, because of two independent
mutations in the uricase gene occurring 10–20 million years
ago, suggesting adaptive evolution, although the proposed
adaptive advantage remains unclear.2,3 Species lacking uricase
have up to 10-fold higher serum urate levels compared with
other mammals.
Uric acid behaves as a weak acid (pKa1 5.75) and occurs
predominantly (98%) as urate anion at physiological pH,
although more is in the uric acid form in urine at pHB5–6,
which affects its solubility and transport.4 Urate anion cannot
readily pass through cell membranes in the absence of
transporters. The water solubility of monosodium urate is
limited (405 mmol/l) so that urate often exists in plasma
at concentrations close to or above this limit, in a state of
supersaturation, when there is an increasing risk of crystal
deposition. Uric acid is substantially less soluble than the
anion in urine at pH 5.
GENOME-WIDE ASSOCIATION STUDIES REVEAL NEW URATE
TRANSPORTERS
Body urate levels reflect the balance of formation and loss.
Urate is formed both from dietary purines (for example,
seafood, meat) and by the metabolism of endogenously
synthesized purines. The major site of urate formation is the
liver, where it is formed from xanthine by the enzyme
xanthine oxidoreductase, which, in its oxidase form, can
form superoxide anion and hydrogen peroxide as
by-products. In the presence of transition metals, these can
form damaging hydroxyl ions, or in the presence of nitric
oxide, peroxynitrite. Xanthine oxidase is abundant in
liver and small intestine but is present in lower amounts in
endothelial cells, brain, kidney, and several other cell types.
Urate is excreted by proximal renal tubules (two-thirds of
daily turnover) and by liver hepatocytes into the bile
canaliculi and gastrointestinal tract (one-third of daily
turnover). Almost all serum urate is initially filtered by the
renal glomeruli but about 90% is reabsorbed into the
blood. In humans, this is achieved by proximal renal tubule
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transporters, such as URAT1 (encoded by the SLC22A12
gene), a member of the major facilitator superfamily.5
The major facilitator superfamily are secondary carriers
(facilitated transport) capable of carrying small molecule
solutes down chemiosmotic ion gradients. URAT1 exchanges
intracellular anions for filtered urate and is expressed on
the apical surface of the proximal renal tubules—facing the
lumen—whereas the basolateral transporter carrying urate
through to the interstitial fluid and blood was until recently
unknown.
Last year, four groups independently identified one or
more variants in the SLC2A9 gene that exerts a major
influence on serum urate concentrations following genome-
wide association studies (GWAS).6–9 SLC2A9 was known to
encode GLUT9, a class II glucose/fructose transporter,10 and
common variants were found to be associated with 5–6% of
the variance in serum urate in females and 1–2% in males.
The identified variants were also associated with gout and
low-fractional excretion of uric acid.8,9,11 Surprisingly,
GLUT9 was then shown to be a high-capacity/low-affinity
(KmB1 mmol/l) urate transporter using Xenopus oocytes.
8
This has since been confirmed by four other groups.11–14
The urate transport activity of GLUT9 is 45- to 60-fold faster
than glucose/fructose transport.11 In one study, in which the
membrane potential was carefully controlled, GLUT9-
mediated urate transport was shown to be electrogenic—
resulting in charge imbalance across the cell membrane—and
strongly voltage dependent,14 suggesting that urate is trans-
ported with a net negative charge into the cell. Large changes
in the transmembrane gradients of either Naþ or Cl did not
influence GLUT9-mediated urate transport rate and reports
of trans-stimulation by glucose or fructose were contra-
dictory,11,12,14,15 so it is unclear whether trans-stimulation is
secondary to membrane potential changes. The simplest
model that fits the current data is that GLUT9 functions as
a urate anion uniporter, but it may also show a parallel,
weakly coupled exchange transporter function.14 A GLUT9
urate uniporter is now widely believed to represent the
missing basolateral membrane exit pathway in proximal renal
tubules, which would be facilitated by, rather than working
against, the cell’s negative membrane potential. In contrast,
the apical uptake of urate from the tubular lumen occurs
through a nonelectrogenic mechanism using the urate-anion
exchanger URAT1.5 However, analysis of GLUT9 isoforms
suggests a more complex picture.
GLUT9 has two isoforms, both of which transport urate
in oocytes and are expressed in proximal renal tubular
cells.8,11,13,16 Isoform 1 (GLUT9) is most strongly expressed
in basolateral membranes of proximal renal tubular cells, as
well as in liver and pancreas, whereas isoform 2 (GLUT9DN)
is most strongly expressed in apical membranes of proximal
renal tubules and placenta.16 This begs the question as to the
function of a potentially electrogenic apical urate transporter.
Current models of renal urate transport in humans involve
free filtration by glomeruli, most of which is reabsorbed
by proximal convoluted tubules, a proportion of which is
secreted back into the urine, so that about 10% of filtered
urate is finally excreted.17 The GLUT9DN isoform may
therefore have a role in apical secretion (down the electrical
gradient), perhaps in exchange for glucose15 or in facilitating
urate uptake from the lumen (down the concentration
gradient but against the electrical gradient), perhaps
indirectly coupled to the secretion of an anion.8 GLUT9 is
also expressed in chondrocytes from articular cartilage,
raising interesting questions about its role in gout. GLUT9-
mediated urate transport in oocytes shows limited sensitivity
to conventional uricosuric drugs, such as benzbromarone,
probenecid, or losartan,8,11,12 but is sensitive to the glucose-
transport inhibitor phloretin.14
Until recently, the transport of urate in and out of the liver
was poorly understood. Dogs express uricase but Dalmatians
were recently shown to have a mutation in SLC2A9,
associated with raised plasma urate and increased urinary
excretion of urate.18 The raised serum urate appears to result
from failure of GLUT9 to transport urate from the sinusoidal
blood vessels into the basolateral surface of liver hepatocytes
for destruction by uricase, whereas renal reuptake of filtered
urate is also blocked (perhaps at the basolateral transporter
step in proximal tubules), resulting in excessive urinary
excretion and recurrent urate stone formation. It is likely that
urate transport into human liver, where GLUT9 is strongly
expressed, is also mediated by this transporter. A complete
Slc2a9 knockout mouse was also recently reported to show
increased blood and urinary urate.19 This was again
attributed to impaired urate transport into hepatocytes and
destruction by uricase, as well as severely impaired renal urate
reabsorption in the distal convoluted tubules, where mouse
Slc2a9 was mainly located, in contrast to the human kidney.
An early-onset urate nephropathy was also present, with
tubulointerstitial inflammation and fibrosis secondary to uric
acid crystal deposition and severe hyperuricosuria.
A follow-up meta-analysis of serum urate GWAS of 11,847
normal individuals from the Framingham and Rotterdam
cohorts, revealed two loci in addition to SLC2A9 that
are associated with both serum urate and gout.20 These
loci explained 1.3% (ABCG2) and 0.7% (SLC17A3) of
the variance in serum urate levels compared with 5.3%
for SLC2A9 in the Framingham cohort. ABCG2 encodes an
ATP binding cassette transporter, expressed in the apical
membranes of several tissues, including liver and human
proximal renal tubular cells, where it transports a wide
variety of substrates, including urate.21 Recently, ABCG2
has been shown to encode a high-capacity urate secretion
transporter.21,22 Several loss-of-function ABCG2 variants
have also been identified that confer an increased risk of
gout, including a common missense mutation (Q141K)
within the nucleotide binding domain (next to the equivalent
phenylalanine residue commonly mutated in cystic fibrosis),
which was shown to reduce urate efflux in Xenopus oocytes
by 53%.21 This variant appears to be the causal ABCG2
variant associated with raised serum urate and gout in GWAS
meta-analyses.20,23 It confers an adjusted odds ratio of
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1.68 per allele for gout and has a minor allele frequency of 3%
in blacks, 11% in whites, and about 30% in Asians. Other
loss-of-function variants have been identified in the Japanese
population (for example, Q126X in 5% of Japanese) so that
variants at the ABCG2 locus have been estimated to account
for about 10% of gout cases in both Caucasian and Japanese
populations.21,22 The equivalent ‘population attributable
risk’—the proportional reduction in disease incidence if the
associated variants could be removed from the population—
for SLC2A9 is 55% of gout cases, because a very common
SLC2A9 allele (frequency B77%) is associated with raised
serum urate and the odds ratio for gout is similar to ABCG2,
at 1.4 per allele.8 Population attributable risk figures are
multiplicative, so that the combined reduction in gout due
to these two loci would be 41% (0.9 0.45). However, these
population attributable risk figures cannot be taken too
literally because they ignore gene–environment interactions
and assume a simple genetic model.
The second new urate locus includes SLC17A1 (encoding
NPT1), SLC17A3 (NPT4), and SLC17A4. NPT1 is expressed
on the apical surface of human proximal renal tubules, which
is capable of voltage-sensitive transport of urate in model
systems and has also been suggested to be a urate secretor.24
The neighboring SLC17A3 locus, which encodes a sodium
phosphate cotransporter (NPT4), is expressed in liver,
intestines, and weakly in kidney. In the rat, NPT4 is also
localized to the apical surface of proximal renal tubular cells
and can transport urate in transfected HEK293 cells.24 It is
unclear whether one or both (NPT1/NPT4) loci influence
serum urate levels. The SLC17A1/SLC17A3 region was also
associated with gout in white Caucasians (odds ratio 1.19,
(major) allele frequency 0.53), which could potentially
explain another one-third or so of gout cases in the
population.
The complexity of urate transport increased further
with the publication of a very large meta-analysis including
28,141 participants from 14 GWAS.23 This study revealed a
total of nine loci influencing serum urate concentrations.
These include the previously reported SLC2A9, ABCG2, and
SLC17A1 (rather than SLC17A3) loci but also three more
membrane transporters in the solute carrier (SLC) family, all
of which are expressed in the kidney: SLC22A11 (encoding
organic acid transporter OAT4), SLC22A12 (encoding
URAT1), and SLC16A9 (encoding the monocarboxylate
co-transporter MCT9). The latter is expressed in several
tissues including the kidney but is relatively uncharacterized
but OAT4 is known to be an organic anion-dicarboxylate
exchanger that can mediate apical urate transport in
proximal renal tubules.25 The other new proteins meeting
the genome-wide significance threshold include, first, the
glucokinase regulator gene (GCKR), which could decrease
renal urate clearance as a result of increased insulin resis-
tance;26 second, the LRRC16A gene encodes a cytoskeletal
protein (Carmil); third, the PDZK1 scaffold protein, which is
implicated in the functional coupling of urate transporters
such as URAT1, OAT4, and NPT1 (urate transportosome).25,27
The precise function of these proteins in the context of urate
regulation is unclear. However, the picture is emerging of
a complex interplay of urate transporters located along the
proximal tubule (Figure 1).
PHYSIOLOGICAL ROLE OF URATE
The physiological role of urate—assuming it has one—is
unclear but it contributes about 60% of plasma antioxidant
activity.28 It is a free radical scavenger that is particularly
effective against peroxynitrite, but also scavenges superoxide,
hydroxyl ions, and singlet oxygen as well as reducing oxidant
formation by chelating iron. It prevents oxidation of low-
density lipoprotein particles and inactivation of superoxide
dismutase. However, its radical scavenging activity relies on
adequate recycling by ascorbate and glutathione. It has been
argued that while urate is an antioxidant in plasma at
‘normal’ concentrations, increased levels within cells can have
pro-oxidant activity, where some of its proposed disease-
associated activities operate.29 For example, urate induces
oxidative and inflammatory damage to adipocytes,30 as well
as inhibiting insulin mediated nitric oxide release from
endothelial cells, which reduces glucose uptake by skeletal
muscle, both of which may contribute to insulin resistance.31
Recently, monosodium urate crystals have been shown to
activate the NALP3 inflammasome, causing the production
of active IL-1b and suggesting an important adjuvant
role in the innate immune response, as well as elucidating
the mechanism of inflammation in gout.32,33 These obser-
vations are also consistent with reported associations bet-
ween hyperuricemia and various inflammatory diseases,
including multiple sclerosis, hypertension, and cardio-
vascular diseases.34
URATE AND DISEASE
The role of urate in diseases other than gout has been
reviewed in detail by others,29,31,34–36 so here we briefly
highlight some new findings thrown up by the discovery of
new urate transporters and the use of genetic variants
influencing urate in disentangling cause-and-effect relation-
ships in diseases associated with hyperuricemia.
There are well-established associations of serum urate with
mortality and risk of cardiovascular or renal disorders—
including coronary artery disease, hypertension, metabolic
syndrome, chronic kidney disease, stroke, peripheral vascular
disease, vascular dementia, and preeclampsia—but cause-
and-effect relationships remain unclear.36 Variants in the
genes recently associated with serum urate provide a
powerful means of investigating cause-and-effect relation-
ships in these and other urate-associated disorders by
‘Mendelian randomization’ or instrumental variable
approaches (Figure 2).37 The rationale here is that the laws of
Mendelian segregation normally ensure that the effects of
genetic variation directly influencing an intermediate trait,
such as serum urate, that is associated with a specific disease
outcome, are unconfounded. Genetic variation in a urate
transporter such as SLC2A9 can therefore function as a proxy
448 Kidney International (2010) 78, 446–452
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for variation in serum urate that is generally independent of
confounding influences on disease. The first assumption is
therefore that there is indeed no confounding of genotypic
effect on outcome. The second is that the genetic variants do
not have other (pleiotropic) effects that could influence
confounders. The third is that there is no developmental or
physiological compensatory change that attenuates the
primary genetic effect on outcome. The analysis can be
performed in a regression framework by comparing the
observed effect of intermediate trait (serum urate) on disease
with the expected effect assuming a causal relationship,
based on the (unconfounded) genotypic effect on both trait
and disease.
Raised serum urate has long been known to be associated
with cardiovascular outcomes such as hypertension: about
one-half of untreated primary hypertensives have hyper-
uricemia. If urate is causally associated with hypertension,
rather than secondary to an associated condition such as
obesity or renal disease, then SLC2A9 variants should also be
associated with hypertension. In one large study, including 4
population cohorts (411,000 people) and 6 hypertension
case–control series (5249 cases),11 there was no association
between SLC2A9 single-nucleotide polymorphisms and either
blood pressure or hypertension. In our study,8 there was
no evidence of association between variants in SLC2A9 and
systolic blood pressure (N¼ 5231), diastolic blood pressure
Confounding factors
(e.g., pro-inflammatory state)
Genetic variation in SLC2A9
and/or other loci directly
influencing serum urate
Serum urate
concentration
(risk factor)
Clinical outcome
(e.g., cardiovascular,
metabolic disease)
Figure 2 |Principles underlying Mendelian randomization as a means of causal inference to dissect the role of uric acid in human
disease.
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Figure 1 |Model of urate transport in the proximal convoluted tubules (PCT) of the kidney. Proteins influencing urate transport in the
kidney identified by recent genome-wide association studies (GWAS)23 are shown in red and others are shown in green. GLUT9 (isoform 1) is
thought to be the major basolateral urate transporter in renal tubular cells contributing to the reabsorption of urate into the blood and
interstitial fluid. The apical URAT1 transporter is proposed to exchange urate anion for organic anions such as lactate and is functionally
coupled to sodium monocarboxylate cotransporters (SMCT1, SMCT2) that transport lactate into the cell driven by an inward sodium
gradient.49 The PDZK1 scaffold protein is thought to bind urate transporters such as URAT1, OAT4, and NPT1, and may form a bidirectional
transport system (transportosome) that can functionally couple different transporters. The role of GLUT9DN (isoform 2) on apical PCT
membranes is unclear but has been proposed to exchange luminal glucose for intracellular urate15 although the data of Dinour et al.43
argue against this. It may mediate urate entry into PCT cells indirectly coupled to the export of an as yet unidentified anion. Other proteins
concerned with the apical reabsorption of urate include the organic anion exchanger OAT4 (SLC22A11). Proteins mediating urate secretion
into urine by PCT cells have also been clarified by recent GWAS (see text). These are proposed to include the apical PCT transporters ABCG2,
NPT1, and NPT4, whereas other evidence supports a role for MRP4 and UAT/galectin-9, which may constitutively excrete urate produced by
intracellular metabolism.
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(N¼ 5231), type 2 diabetes (N¼ 4789 cases compared with
5295 controls), with fasting measures of glucose (N¼ 2069)
or insulin (N¼ 801), with waist circumference (N¼ 5222),
triglyceride (N¼ 5222), or high-density lipoprotein choles-
terol (N¼ 5187).8 Individuals with a combination of these
trait values above given thresholds are regarded as having
‘metabolic syndrome’, which is associated with increased risk
and mortality from cardiovascular disease.38,39 The known
association of serum urate with metabolic syndrome39,40 was
clearly evident in this study8 in which 78% of the gout cases
had metabolic syndrome. However, the lack of association
between SLC2A9 single-nucleotide polymorphisms and
metabolic syndrome (NCEP ATP III definition) in 3571
cases and 1678 controls, or with its component traits, showed
that serum urate is unlikely to have a causal relationship with
these cardiovascular or metabolic diseases. This does not
exclude a role for intracellular rather than extracellular urate
concentrations in the pathogenesis of these disorders because
it is unclear to what extent variants in GLUT9 and other
urate modifying transporters influence intracellular urate.
Raised serum urate is also associated with chronic renal
damage, apparently independently of reduced glomerular
filtration rates or urate crystal deposition, although it is
unclear whether it is independent of associated hypertension.
Essentially all untreated gout patients show characteristic
renal lesions but most of these changes are also found in
hypertensive nephropathy.41 Similar renal lesions are found
in hyperuricosemic rats, together with activation of the
renin–angiotensin system.42 This provides another opportu-
nity to explore the association of urate transporter single-
nucleotide polymorphisms with renal disease and to dissect
cause-and-effect relationships. No genome-wide significant
association was identified between single-nucleotide poly-
morphisms influencing serum urate and chronic kidney
disease, although variants at the uromodulin (UMOD) locus
were associated with chronic kidney disease. Rare mutations
in UMOD cause both hyperuricemia and autosomal
dominant forms of chronic kidney disease (see below).
Autosomal recessive mutations in the URAT1 trans-
porter can lead to nephrolithiasis and about 10% develop
exercise-induced acute renal failure. Average serum urate
levels in homozygotes are 55 mmol/l (normal range
B240–350 mmol/l). Recently, Dinour et al.43 showed that
individuals with homozygous deletion or missense mutations
in SLC2A9 have severe hypouricemia, with very low or
unmeasurable serum urate (mean 10 mmol/l) and high-
fractional excretion of uric acid (4150%). The latter
is probably due to both reduced urate reabsorption and
continuing renal secretion by other transporters, because
urate transport in Xenopus oocytes injected with SLC2A9
mRNA from an affected subject was severely reduced. Some
affected individuals also had episodes of exercise-induced
acute renal failure, which was proposed to result from
reduced serum antioxidant capacity in the face of exercise-
induced increases in reactive oxygen species, leading to renal
vasoconstriction and an ischemic type of acute renal failure.43
Heterozygous SLC2A9 mutations have also been associated
with exercise-induced acute renal failure, with less severe
hypouricemia.12,13 These data provide definitive evidence
that GLUT9 is involved in the renal reabsorption of uric
acid—probably as the major basolateral transporter in
proximal tubules—and suggest that it is not a major urate
secretor.
Familial juvenile hyperuricemic nephropathy is one of
three rare autosomal dominant kidney disorders caused by
UMOD mutations associated with low fractional excretion of
urate, hyperuricemia, and interstitial nephropathy, which can
progress to end-stage renal failure.44 UMOD is an abundant
urinary protein (Tamm–Horsfall protein) that is secreted by
renal tubular epithelial cells located in the ascending limb
of the loop of Henle. UMOD mutations that cause familial
juvenile hyperuricemic nephropathy predominantly give rise
to misfolded proteins that are retained in the endoplasmic
reticulum rather than being anchored to the plasma
membrane, cleaved, and secreted into urine.44 The function
of the Tamm–Horsfall protein remains unclear but it has
been suggested to have a role in the immune response to
infection.45
Potential for new uricosuric drugs
Major facilitator superfamily transporters have the ability
to differentiate between large numbers of structurally
similar, small, or medium sized hydrophilic molecules, so
are regarded as ‘druggable’ targets.46 At present, asympto-
matic individuals with hyperuricemia are not treated unless
they have very high plasma or urinary urate levels or are due
for chemotherapy/radiotherapy. This may change because
genetic testing with SLC2A9, ABCG2, and SLC17A3 can show
up to 40-fold differences in risk of gout.20 In acute gout,
treatment is currently dominated by anti-inflammatory
agents rather than urate lowering drugs, although IL-1
antagonists, such as anakinra or IL-1 Trap (rilonacept), show
considerable promise for reducing inflammation in acute and
chronic gout.47 Prevention of gout and hyperuricemia using
xanthine oxidase inhibitors, such as allopurinol or febuxo-
stat, is the first-line of treatment, aiming to keep urate
o360 mmol/l, as well as in patients with urate calculi, renal
insufficiency, concomitant diuretic, and cyclosporine therapy,
or if there is urate overproduction. However, the usefulness
of allopurinol can be limited by drug dosing and intolerance,
drug interactions, and treatment failure so that, in one study,
only 21% achieved optimal urate concentrations.48 Allo-
purinol can also cause rare but serious complications,
especially the potentially fatal Stevens–Johnson syndrome.
Uricosuric drugs such as probenecid, benzbromarone, or
losartan are the urate-lowering drugs of choice in allo-
purinol-allergic patients and urate under-excretors with
normal renal function and no history of urolithiasis. How-
ever, these drugs rarely achieve low intracellular urate levels.31
Prevention of acute gout can be effectively achieved if the
patient shows good compliance but maximum benefit may
require low intra- and extracellular urate concentrations.
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GLUT9 shows a different sensitivity profile to current urico-
suric agents so GLUT9 inhibitors could be valuable. The
occurrence of exercise-induced acute renal failure in subjects
with genetically reduced GLUT9 transport occurs in the
context of almost unmeasurable serum urate levels, so is
highly unlikely to be a problem in individuals with urate
levels in the 240–350 mmol/l range. Other urate transporter
candidates identified in GWAS also merit investigation in this
context.
The role of hyperuricemia in innate immunity and
common diseases is an expanding area of current research.
Future areas of interest include clarification of cause-
and-effect relationships using Mendelian randomization,
and the elucidation of urate transport mechanisms in liver,
kidney, joints, and other tissues. The recent progress in
robustly identifying genes influencing urate transport and
metabolism represents one of the success stories of GWAS
but it remains to be seen whether patient benefit will follow.
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